Agenus Falls After $141M Zydus Deal Closes

Dow Jones

01/16

By Katherine Hamilton

Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.

Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.

Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.

The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.

Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.

Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 15, 2026 13:29 ET (18:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603980629"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603980629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603980629?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603980629","market":"hk","top_or_hot":-1,"title":"Agenus Falls After $141M Zydus Deal Closes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Falls After $141M Zydus Deal Closes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Falls After $141M Zydus Deal Closes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 02:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603980629","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603980629","pubTimestamp":1768501740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"1.41亿美元Zydus交易完成后Agenus股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n\n\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n\n\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n\n\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n\n\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n\n\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 13:29 ET (18:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}